lorazepam has been researched along with Attention Deficit Disorder with Hyperactivity in 5 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Attention Deficit Disorder with Hyperactivity: A behavior disorder originating in childhood in which the essential features are signs of developmentally inappropriate inattention, impulsivity, and hyperactivity. Although most individuals have symptoms of both inattention and hyperactivity-impulsivity, one or the other pattern may be predominant. The disorder is more frequent in males than females. Onset is in childhood. Symptoms often attenuate during late adolescence although a minority experience the full complement of symptoms into mid-adulthood. (From DSM-V)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Hyperactivity, impulsivity, and inattention improved with lorazepam, suggesting that the attention-deficit/hyperactivity disorder symptoms could be manifestations of catatonia." | 7.73 | PANDAS with catatonia: a case report. Therapeutic response to lorazepam and plasmapheresis. ( Ahmed, AA; Balamuth, N; Dell, ML; Elia, J; Friedman, DF; Pati, S; Zimmerman, RA, 2005) |
| " Hyperactivity, impulsivity, and inattention improved with lorazepam, suggesting that the attention-deficit/hyperactivity disorder symptoms could be manifestations of catatonia." | 3.73 | PANDAS with catatonia: a case report. Therapeutic response to lorazepam and plasmapheresis. ( Ahmed, AA; Balamuth, N; Dell, ML; Elia, J; Friedman, DF; Pati, S; Zimmerman, RA, 2005) |
| "The prognosis of CCI patients with coma or delirium has not yet been thoroughly studied, but preliminary studies suggest this population is at high risk for detrimental outcomes associated with acute brain dysfunction." | 2.48 | Brain dysfunction in patients with chronic critical illness. ( Girard, TD, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shrivastava, SVK | 1 |
| Poulsen, R | 1 |
| Mavrides, N | 1 |
| Coffey, BJ | 1 |
| Santos-Cubiñá, J | 1 |
| Torres-Rodríguez, A | 1 |
| Castaing-Lespier, PA | 1 |
| Sabaté, N | 1 |
| Torres-Martin, A | 1 |
| Carlo, S | 1 |
| Girard, TD | 1 |
| Elia, J | 1 |
| Dell, ML | 1 |
| Friedman, DF | 1 |
| Zimmerman, RA | 1 |
| Balamuth, N | 1 |
| Ahmed, AA | 1 |
| Pati, S | 1 |
| Spalletta, G | 1 |
| Caltagirone, C | 1 |
1 review available for lorazepam and Attention Deficit Disorder with Hyperactivity
| Article | Year |
|---|---|
Brain dysfunction in patients with chronic critical illness.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Chronic Disease; Coma; Comorbid | 2012 |
4 other studies available for lorazepam and Attention Deficit Disorder with Hyperactivity
| Article | Year |
|---|---|
Catatonia in a 12-Year-Old Child.
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Catatonia; Central Nervous System St | 2021 |
Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.
Topics: Adult; Antidepressive Agents; Antimanic Agents; Attention Deficit Disorder with Hyperactivity; Benzo | 2013 |
PANDAS with catatonia: a case report. Therapeutic response to lorazepam and plasmapheresis.
Topics: Attention Deficit Disorder with Hyperactivity; Autoimmune Diseases; Basal Ganglia Diseases; Catatoni | 2005 |
Why the use of benzodiazepines a few minutes before the imaging does not affect cerebral blood flow results in single photon emission computed studies.
Topics: Attention Deficit Disorder with Hyperactivity; Benzodiazepines; Brain; Cerebrovascular Circulation; | 2007 |